Compare · ABT vs NTHI
ABT vs NTHI
Side-by-side comparison of Abbott Laboratories (ABT) and NeOnc Technologies Holdings Inc. (NTHI): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both ABT and NTHI operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- ABT is the larger of the two at $158.13B, about 1436.1x NTHI ($110.1M).
- ABT has been more active in the news (27 items in the past 4 weeks vs 19 for NTHI).
- ABT has more recent analyst coverage (25 ratings vs 1 for NTHI).
- Company
- Abbott Laboratories
- NeOnc Technologies Holdings Inc.
- Price
- $90.64-0.80%
- $4.37+6.59%
- Market cap
- $158.13B
- $110.1M
- 1M return
- -11.68%
- -
- 1Y return
- -30.71%
- -
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NYSE
- NASDAQ
- IPO
- News (4w)
- 27
- 19
- Recent ratings
- 25
- 1
Abbott Laboratories
Abbott Laboratories discovers, develops, manufactures, and sells health care products worldwide. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The Established Pharmaceutical Products segment provides generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorder, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism, Ménière's disease and vestibular vertigo, pain, fever, inflammation, and migraine, as well as provides anti-infective clarithromycin, influenza vaccine, and products to regulate physiological rhythm of the colon. The Diagnostic Products segment offers laboratory systems in the areas of immunoassay, clinical chemistry, hematology, and transfusion; molecular diagnostics systems that automate the extraction, purification, and preparation of DNA and RNA from patient samples, as well as detect and measure infectious agents; point of care systems; cartridges for testing blood; rapid diagnostics lateral flow testing products; molecular point-of-care testing for HIV, SARS-CoV-2, influenza A and B, RSV, and strep A; cardiometabolic test systems; drug and alcohol test, and remote patient monitoring and consumer self-test systems; and informatics and automation solutions for use in laboratories. The Nutritional Products segment provides pediatric and adult nutritional products. The Medical Devices segment offers rhythm management, electrophysiology, heart failure, vascular, and structural heart devices for the treatment of cardiovascular diseases; and diabetes care products, as well as neuromodulation devices for the management of chronic pain and movement disorders. The company was founded in 1888 and is based in North Chicago, Illinois.
Latest ABT
- SEC Form 4 filed by EXECUTIVE VICE PRESIDENT Moreland Mary K
- SEC Form SCHEDULE 13G filed by Abbott Laboratories
- SEC Form 10-Q filed by Abbott Laboratories
- Director Conroy Kevin T was granted 2,286 units of Common shares without par value, increasing direct ownership by 2% to 133,737 units (SEC Form 4)
- New insider Conroy Kevin T claimed ownership of 131,451 units of Common shares without par value (SEC Form 3)
- Director Stratton John G was granted 2,286 units of Common shares without par value, increasing direct ownership by 12% to 21,319 units (SEC Form 4)
- Director Starks Daniel J bought $926,537 worth of Common shares without par value (10,000 units at $92.65) and was granted 2,286 units of Common shares without par value, increasing direct ownership by 0.18% to 6,751,103 units (SEC Form 4)
- Director Roman Michael F was granted 2,286 units of Common shares without par value, increasing direct ownership by 27% to 10,764 units (SEC Form 4)
- Director O'Grady Michael was granted 2,286 units of Common shares without par value, increasing direct ownership by 43% to 7,603 units (SEC Form 4)
- Director Mckinstry Nancy was granted 2,286 units of Common shares without par value, increasing direct ownership by 6% to 41,010 units (SEC Form 4)
Latest NTHI
- President Heshmatpour Amir F bought $45,180 worth of shares (10,000 units at $4.52), increasing direct ownership by 0.33% to 3,062,000 units (SEC Form 4)
- Chief Clinical Officer Neman-Ebrahim Yousha bought $2,440 worth of shares (500 units at $4.88), increasing direct ownership by 0.37% to 134,760 units (SEC Form 4)
- CFO Garnett Keithly bought $1,614 worth of shares (300 units at $5.38), increasing direct ownership by 0.12% to 241,200 units (SEC Form 4)
- NeOnc Technologies Holdings Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Financial Statements and Exhibits
- BTIG Research initiated coverage on NeOnc Technologies Holdings with a new price target
- President Heshmatpour Amir F bought $49,000 worth of shares (10,000 units at $4.90), increasing direct ownership by 0.33% to 3,052,000 units (SEC Form 4)
- SEC Form EFFECT filed by NeOnc Technologies Holdings Inc.
- NeOnc Technologies Holdings Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits
- SEC Form 424B5 filed by NeOnc Technologies Holdings Inc.
- NeOnc Technologies Holdings, Inc. Announces ~ $300,000 in Insider Purchases of NTHI Stock by Chairman and CEO; Company Provides Context on 2025 Financial Results